ArticleCureus2026
Evaluation of Recombinant Follicle-Stimulating Hormone (rFSH) Plus Recombinant Luteinizing Hormone (rLH) and rFSH Plus Human Menopausal Gonadotropin (HMG) Combination Therapies in Patients With Poor Ovarian Response Undergoing Ovarian Stimulation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to compare the clinical and laboratory outcomes of recombinant follicle-stimulating hormone (rFSH) plus recombinant luteinizing hormone (rLH) and rFSH plus human menopausal gonadotropin (HMG) combination therapies during controlled ovarian hyperstimulation (COH) in patients with poor ovarian response, with the live birth rate defined as the primary clinical endpoint.
methodsThis retrospective study included 90 patients who were diagnosed with poor ovarian response based on the Bologna criteria (which were also categorized as Poseidon Groups 3 and 4) and who met the inclusion requirements. Patients were divided into two groups based on the gonadotropin combination used: rFSH+rLH (n=49) and rFSH+HMG (n=41). Stimulation parameters, number of oocytes retrieved, embryo quality, and live birth rates were analyzed and compared.
resultsNo statistically significant differences were found between the groups regarding age, hormone levels, antral follicle count (AFC), duration of COH, number of retrieved oocytes, M2 oocyte ratio, fertilization rate, or live birth rates (p>0.05).
conclusionOur findings suggest that both rFSH+rLH and rFSH+HMG combinations yielded similar clinical and laboratory outcomes in patients with diminished ovarian reserve. Given the observational nature of this study, these results should be interpreted with caution, and treatment protocols should remain individualized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.